Financial Consulate’s Zevra Therapeutics ZVRA Stock Holding History

Financial Consulate’s Portfolio ZVRA Stock Details ZVRA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$1.65K	Buy	+150	New	+$1.78K	﹤0.01%	1170

Other funds holding ZVRA

Retirement Planning Company of New England Warwick, Rhode Island $263M AUM 26.23% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

MAM

Mystic Asset Management Warwick, Rhode Island $451M AUM 22.13% 1-Year Est. Return

Inspire Investing Meridian, Idaho $2.37B AUM 29.82% 1-Year Est. Return

IFG Advisors St. Louis, Missouri $730M AUM 19.37% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Quaker Wealth Management Moorestown, New Jersey $341M AUM 9.06% 1-Year Est. Return

Bailard Foster City, California $4.94B AUM 25.15% 1-Year Est. Return

City State Bank Norwalk, Iowa $441M AUM 23.97% 1-Year Est. Return

State of Alaska Department of Revenue Juneau, Alaska $9.6B AUM 34.67% 1-Year Est. Return

Financial Consulate's ZVRA Position: Q3 2026 in Review

Financial Consulate opened a new position in Zevra Therapeutics (ZVRA) in Q3 2026: 150 shares worth $1.65K. The stake represents ﹤0.01% of the portfolio and ranks #1170 among its holdings.

23 funds tracked by Wall St. Rank hold ZVRA as of Q3 2026.

Financial Consulate held 150 shares of Zevra Therapeutics worth $1.65K as of Q3 2026.
Zevra Therapeutics was a new Financial Consulate position in Q3 2026.
Zevra Therapeutics made up ﹤0.01% of Financial Consulate's portfolio in Q3 2026, its #1170 holding.
23 funds tracked by Wall St. Rank held Zevra Therapeutics as of Q3 2026.

Based on Financial Consulate's 13F filing for Q3 2026, filed 23 Oct 2026.